A randomized, double-blind, placebo-controlled phase3 clinical trial of OCV-C01 for patients with pancreatic cancer refractory to standard therapy
Phase of Trial: Phase III
Latest Information Update: 16 May 2016
At a glance
- Drugs OCV C01 (Primary)
- Indications Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms COMPETE-PC; R000008586
- Sponsors OncoTherapy Science
- 20 Dec 2013 Primary endpoint 'Overall-survival' has not been met.
- 20 Dec 2013 Status changed from recruiting to discontinued, as reported in an OncoTherapy Science media release.
- 19 Dec 2013 Results published in the Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History